ES2094750T3 - Nuevos derivados hidrofilos, aplicaciones en diagnostico y terapia, estuches de diagnostico o terapeuticos y reactivos inmunologicos. - Google Patents

Nuevos derivados hidrofilos, aplicaciones en diagnostico y terapia, estuches de diagnostico o terapeuticos y reactivos inmunologicos.

Info

Publication number
ES2094750T3
ES2094750T3 ES90430018T ES90430018T ES2094750T3 ES 2094750 T3 ES2094750 T3 ES 2094750T3 ES 90430018 T ES90430018 T ES 90430018T ES 90430018 T ES90430018 T ES 90430018T ES 2094750 T3 ES2094750 T3 ES 2094750T3
Authority
ES
Spain
Prior art keywords
diagnostic
immunological reagents
therapy applications
hydrophilic derivatives
new hydrophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90430018T
Other languages
English (en)
Inventor
Jacques Barbet
Michel Delaage
Anne Gruaz-Guyon
Jean-Marc Le Doussal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunotech SAS
Original Assignee
Immunotech Partners SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotech Partners SA filed Critical Immunotech Partners SA
Application granted granted Critical
Publication of ES2094750T3 publication Critical patent/ES2094750T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

DERIVADOS QUE COMPRENDEN DOS HAPTENOS HIDROFILOS Y UN GRUPO EFECTOR CONSTITUIDO POR UN ISOTOPO RADIOACTIVO O CONOCIDO PARA PODER SER MARCADO POR UN ISOTOPO RADIOACTIVO O CONSTITUIDO DE UN PRINCIPIO ACTIVO O CONOCIDO PARA PODER FIJAR UN PRINCIPIO ACTIVO, UNIDOS POR UNA CADENA DE CONEXION: APLICACION AL DIAGNOSTICO Y A LA TERAPIA, KITS DIAGNOSTICOS O TERAPEUTICOS Y REACTIVOS INMUNOLOGICOS CONTENIENDOLOS.
ES90430018T 1989-09-21 1990-09-20 Nuevos derivados hidrofilos, aplicaciones en diagnostico y terapia, estuches de diagnostico o terapeuticos y reactivos inmunologicos. Expired - Lifetime ES2094750T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8912622A FR2652004B1 (fr) 1989-09-21 1989-09-21 Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.

Publications (1)

Publication Number Publication Date
ES2094750T3 true ES2094750T3 (es) 1997-02-01

Family

ID=9385847

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90430018T Expired - Lifetime ES2094750T3 (es) 1989-09-21 1990-09-20 Nuevos derivados hidrofilos, aplicaciones en diagnostico y terapia, estuches de diagnostico o terapeuticos y reactivos inmunologicos.

Country Status (11)

Country Link
US (1) US5274076A (es)
EP (1) EP0419387B1 (es)
JP (1) JP2914737B2 (es)
KR (1) KR0166075B1 (es)
AT (1) ATE145338T1 (es)
AU (1) AU638488B2 (es)
CA (1) CA2025607C (es)
DE (1) DE69029184T2 (es)
DK (1) DK0419387T3 (es)
ES (1) ES2094750T3 (es)
FR (1) FR2652004B1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5562894A (en) * 1991-08-09 1996-10-08 Regents Of The University Of California Amino-acyl-type and catecholamine-type contrast agents for MRI
CA2115275A1 (en) * 1991-08-09 1993-02-18 David L. White Amino acid, ester and/or catechol contrast agents for mri
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
CA2094785A1 (en) * 1992-05-08 1993-11-09 Jean Gariepy Metal chelating peptide
US6228362B1 (en) 1992-08-21 2001-05-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
FR2697255B1 (fr) * 1992-10-27 1995-01-13 Immunotech Partners Nouveaux dérivés bihaptènes liant le technétium, application au diagnostic et à la thérapeutique, kits et réactifs immunologiques les mettant en Óoeuvre.
DE4428874A1 (de) * 1994-08-08 1996-02-22 Schering Ag Dimere DTPA-Derivate und deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik und Therapie sowie Verfahren zur Herstellung der Komplexe und Mittel
DE19533477C2 (de) * 1995-09-12 1997-10-23 Pharma Beratung Dr Klaus Hoffm Verwendung von Diethylentriaminpentaessigsäure (DTPA) mit immunsuppressiver Wirkung
US6558669B1 (en) * 1996-08-28 2003-05-06 Immunomedics, Inc. Stable radioiodine conjugates and methods for their synthesis
US6663866B1 (en) 1996-08-28 2003-12-16 Immunomedics, Inc. Stable radioiodine conjugates and methods for their synthesis
CA2263985A1 (en) * 1996-08-28 1998-03-05 Immunomedics, Inc. Stable radioiodine conjugates and methods for their synthesis
US7521531B2 (en) * 1996-08-28 2009-04-21 Immunomedics, Inc. Methods for the purification of stable radioiodine conjugates
US20040096394A1 (en) * 1996-08-28 2004-05-20 Immunomedics, Inc. Stable radioiodine conjugates and methods for their systhesis
US6071490A (en) * 1998-05-07 2000-06-06 Immunomedics, Inc. Position emission tomography using gallium-68 chelates
AU740563B2 (en) * 1998-05-07 2001-11-08 Immunomedics Inc. Positron emission tomography using gallium-68 chelates
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US7052872B1 (en) 1999-06-22 2006-05-30 Immunomedics, Inc. Bi-specific antibodies for pre-targeting diagnosis and therapy
US7387772B1 (en) 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
AU760854B2 (en) * 1998-06-22 2003-05-22 Immunomedics Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
FR2816620B1 (fr) * 2000-11-16 2003-02-21 Inst Nat Sante Rech Med Nouveaux composes pour des applications a la radioimmunoscintingraphie et/ou a la radioimmunotherapie des cancers
JP2005501052A (ja) * 2001-07-31 2005-01-13 イムノメディクス， インコーポレイテッド ポリマー送達系
US7230085B2 (en) * 2001-11-28 2007-06-12 Immunomedics, Inc. Anti-DOTA antibody
JP4937751B2 (ja) * 2003-06-13 2012-05-23 イミューノメディクス、インコーポレイテッド Ｄ−アミノ酸ペプチド

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437398A1 (fr) * 1978-06-20 1980-04-25 Commissariat Energie Atomique Compose iode utilisable comme traceur en radio-immunologie
ES8504461A1 (es) * 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
US4479930A (en) * 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
CA1282069C (en) * 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
ES2058492T3 (es) * 1988-02-03 1994-11-01 Hybritech Inc Mejoras en o relativas a haptenos modificados utiles como agentes terapeuticos y de formacion de imagenes.
WO1989007114A1 (en) * 1988-02-08 1989-08-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds

Also Published As

Publication number Publication date
FR2652004A1 (fr) 1991-03-22
DE69029184T2 (de) 1997-06-05
CA2025607C (en) 2001-08-07
ATE145338T1 (de) 1996-12-15
DK0419387T3 (da) 1997-04-07
KR0166075B1 (ko) 1999-01-15
JP2914737B2 (ja) 1999-07-05
EP0419387B1 (fr) 1996-11-20
AU6303490A (en) 1991-03-28
US5274076A (en) 1993-12-28
FR2652004B1 (fr) 1994-10-28
AU638488B2 (en) 1993-07-01
DE69029184D1 (de) 1997-01-02
KR910005862A (ko) 1991-04-27
EP0419387A1 (fr) 1991-03-27
CA2025607A1 (en) 1991-03-22
JPH03173900A (ja) 1991-07-29

Similar Documents

Publication Publication Date Title
ES2094750T3 (es) Nuevos derivados hidrofilos, aplicaciones en diagnostico y terapia, estuches de diagnostico o terapeuticos y reactivos inmunologicos.
ATE130197T1 (de) Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
DE3587724D1 (de) Antikörper verwendende diagnostische Methoden.
DK609985A (da) Adhesin-antigener, antistoffer mod disse og dna-fragmenter, som indkoder antigenerne
DK614987A (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
DE3578625D1 (de) Radioaktiv markierte antikoerperstuecke.
DK0417870T3 (da) Chelatdannere til kompleksbinding af radioaktive isotoper, metalkomplekser deraf samt anvendelsen deraf til diagnostik og terapi
SE7906148L (sv) Forfarande for framstellning av en biologisk komposition for anvendning sasom referenskontroll vid diagnostiska tester
DE69531613D1 (de) Einführung einer thiol-gruppe in proteine für die radioimmundetektion und radioimmuntherapie auf der basis von radionukliden
BR8300656A (pt) Ensaio para determinar a concentracao de antigenos, processo para determinar o periodo fertil do ciclo menstrual, conjunto de reagente, e molecula ligante
SE8300320D0 (sv) Monoclonal antibody formulation for diagnostic use
IT1207589B (it) Composizione di anticorpi monoclonali umani cross-protettivi.
SE8701905D0 (sv) A method and a kit for the diagnosis of iga nephropathy
BE883905A (fr) Tests et reactifs de diagnostic par agglutination
Turner et al. Simple method of subtyping human G-myeloma proteins based on sensitivity to pepsin digestion
DE3862017D1 (de) Pharmazeutische zubereitung zur behandlung von tinea pedis.
DE69014300T2 (de) Radioaktive markierung von proteinen.
DE3650635D1 (de) Monoklonale Antikörper
NO864382D0 (no) Midler for forbedring av proteinabsorpsjon.
SU1425549A1 (ru) Способ радиоиммунологического определени антигенов
FI891898A (fi) HIV-1:een liittyvät polypeptidit, diagnostiset systeemit ja analyysimenetelmät
KR900008276A (ko) 혈액응고작용을 이용한 새로운 항원 · 항체 진단시약
ES2052267T3 (es) Anticuerpos anti-rh(d) humanos modificados.
SE8600543D0 (sv) Diagnostiskt test for detektering av antikroppar i kroppsvetskor
GB1413800A (en) Diagnosis of viral diseases

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 419387

Country of ref document: ES